USA News
Group News Commentary
Issued on behalf of Avant Technologies Inc.
VANCOUVER, BC, Jan. 17,
2025 /CNW/ -- According to experts, soon the
integration of artificial intelligence (AI) into healthcare will
drastically shift from a novelty, to a critical resource. With
over 800 FDA-cleared health AI applications, the new
expectation is that AI will be a game changer. In a new
article from Fast Company, the author predicts health
AI in 2025 will include home testing, AI agents, passive
monitoring, ambient documentation, and autonomous coding. The
World Economic Forum is also highlighting the ways
generative AI could transform clinical trials. According to a new
survey from eClinicalWorks, 90% of healthcare
professionals report a favorable view of AI. Working to provide
these powerful AI tools to the health industry are several
innovators, including new developments from Avant Technologies,
Inc. (OTCQB: AVAI), Recursion Pharmaceuticals, Inc.
(NASDAQ: RXRX), Teladoc Health, Inc. (NYSE: TDOC),
Butterfly Network, Inc. (NYSE: BFLY), and Absci
Corporation (NASDAQ: ABSI).
The article continued: Analysts at market.us are
predicting the Generative AI in Healthcare Market to reach
US$17.2 billion by 2032, growing at a
CAGR of 37% along the way. Researchers at Technavio see an
even bigger future, projecting the Smart Healthcare
Market (including telemedicine, mHealth, smart pills, and AI)
to grow by US$125.7 billion through
to 2028.
Avant Technologies and Ainnova Secure Advanced AI Algorithms
for Early Detection of Four Additional Diseases in the U.S.
Avant Technologies, Inc. (OTCQB: AVAI), an emerging
technology company developing solutions in artificial intelligence
in healthcare, today announced its partner, Ainnova Tech,
Inc., (Ainnova) a leading healthcare technology company
focused on revolutionizing early disease detection using AI, has
acquired an exclusive license for 4 groundbreaking, AI-driven
algorithms from one of Asia's most
respected and largest healthcare institutions. These solutions,
validated across diverse geographies, ethnicities, and
socio-economic populations with data from over 2-million patients,
will join Ainnova's existing diabetic retinopathy and
retinal disease detection solutions.
The 4 algorithms include early detection for cardiovascular
risk, prediabetes and type 2 diabetes, fatty liver disease, and
chronic kidney disease. Combined with Ainnova's existing
retinal disease detection tools, these new algorithms will be used
with Ainnova's powerful cutting-edge AI platform, VisionAI,
to detect the early markers of these diseases quickly and
accurately by applying AI.
The acquisition of an exclusive license to use 4 advanced
algorithms in the Americas offers Ainova Acquisition Corp.
(AAC), the company formed by the partnership between
Avant and Ainnova, a robust platform for primary
care providers to streamline early risk screening and improve
patient care in the United
States.
Ainnova will introduce these cutting-edge solutions in
Latin America with strategic
partners in primary healthcare services across key markets like
Mexico and Brazil. AAC expects to build on
Ainnova's regional expansion by securing clearance from the
U.S. Food and Drug Administration (FDA) in 2025 to
then introduce these solutions in the U.S. market.
"This license represents a pivotal moment for Ainnova and
for its partnership with Avant as it allows us to bring world
class, validated solutions to the Americas," said Vinicio Vargas, CEO of Ainnova. "This
effort not only complements our current solutions, but it also
aligns with our ongoing R&D initiatives to continue
incorporating new diseases that can be detected quickly and
affordably, pushing the boundaries of preventive care, and making
healthcare more inclusive and accessible to all."
CONTINUED… Read this and more news for Avant Technologies
Inc.
https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
Other recent industry developments and happenings in the
market include:
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX), a
clinical-stage biotechnology company that recently combined with
Exscientia, recently reported initial monotherapy
dose-escalation data from the Phase 1/2 study (ELUCIDATE) of
REC-617, a selective CDK7 inhibitor, in advanced solid
tumors. REC-617 was well-tolerated across all dose levels
(2-20 mg QD and 1 mg BID), with most adverse events being mild
(Grade 1-2) and reversible. Notably, one patient with metastatic,
platinum-resistant ovarian cancer achieved a confirmed durable
partial response lasting over 6 months, while four others
experienced stable disease for up to 6 months.
"These initial findings for REC-617 represent an exciting step
forward in the development of CDK7 inhibitors, with a favorable
PK/PD profile and a durable confirmed partial response observed in
dose escalation in a highly pre-treated patient population," said
Najat Khan, Ph.D., Chief R&D
Officer and Chief Commercial Officer, Recursion. "Designed
using our AI-powered OS platform, REC-617 reflects our focus on
enhancing the therapeutic index to deliver more effective and safer
treatment options for patients. We are eager to continue this
momentum in dose escalation and to initiate the next phase of the
program next year."
Teladoc Health, Inc. (NYSE: TDOC), the global leader in
virtual care, recently announced the launch of new AI-enabled
capabilities to enhance its Virtual Sitter solution to improve
patient safety, address workforce challenges, and enhance care
delivery for hospitals and health systems. Teladoc
Health's Virtual Sitter uses AI to allow a single remote
staff member to monitor more patients, boosting inpatient team
capacity by 25%. This innovation complements Teladoc's
connected care solutions, including virtual nursing, physician
consults, and interpretive services, reducing administrative
burdens and improving satisfaction for both clinicians and
patients.
"For more than a decade, we've pioneered new ways for technology
to support human interaction in patient care, helping hospitals and
health systems transform care delivery and meet their most pressing
challenges," said Andy Puterbaugh,
Teladoc Health President of Hospitals and Health Systems.
"New applications of AI are now accelerating our impact, supporting
continuous improvement of our fully integrated suite of connected
care solutions, including Virtual Sitter."
Butterfly Network, Inc. (NYSE: BFLY), a digital health
company transforming care with portable, semiconductor-based
ultrasound technology and intuitive software, in partnership with
HeartFocus, a revolutionary, AI-enabled heart echo software
by data-driven medtech company, recently announced the launch of
the HeartFocus Education app. The HeartFocus Education app uses
AI-powered, self-paced learning to help healthcare practitioners
master 10 essential cardiac views with clinical accuracy in hours.
Officially launched at ANCC MagPath 2024, the app integrates
seamlessly with Butterfly iQ3 and iQ+ probes on iOS iPads, offering
an intuitive, engaging, and high-impact training experience
enhanced by gamification.
"HeartFocus is set to make a big impact in cardiac care,
and we're thrilled to partner with DESKi on this pioneering
education platform," said Darius
Shahida, Chief Strategy Officer at Butterfly Network.
"By combining our cutting-edge ultrasound technology with
HeartFocus' AI-powered training, we're breaking down
barriers to cardiac care, empowering more practitioners to learn
how to deliver critical diagnostics on the spot."
Absci Corporation (NASDAQ: ABSI), a data-first generative
AI drug creation company, recently announced updates and
progress across its internal pipeline of proprietary Drug Creation
programs, as well as new breakthroughs demonstrated by
Absci's AI Integrated Drug Creation™ platform. Absci
leadership and a series of distinguished guest speakers will be
presenting on these updates today at Absci's 2024 R&D Day.
"We are excited to showcase the target and significant
opportunities we see for ABS-201, present new data for ABS-101 and
ABS-301, and introduce ABS-501 to our pipeline. ABS-201, a
potential treatment for male and female pattern hair loss,
represents an opportunity to unlock an entirely new category of
therapy for a substantial consumer-driven market with significant
clinical unmet need," said Sean
McClain, Founder and CEO of Absci. "And as we near
the end of 2024, we see next year as an opportunity to reach
multiple milestones across our internal portfolio, and maintain a
robust pipeline of potential partners across the Pharma and broader
healthcare industry landscape."
Source:
https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
CONTACT:
USA NEWS
GROUP
info@usanewsgroup.com
(604) 265-2873
DISCLAIMER: Nothing in this publication should be
considered as personalized financial advice. We are not licensed
under securities laws to address your particular financial
situation. No communication by our employees to you should be
deemed as personalized financial advice. Please consult a licensed
financial advisor before making any investment decision. This is a
paid advertisement and is neither an offer nor recommendation to
buy or sell any security. We hold no investment licenses and are
thus neither licensed nor qualified to provide investment advice.
The content in this report or email is not provided to any
individual with a view toward their individual circumstances.
USA News Group is a wholly-owned
subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been
paid a fee for Avant Technologies Inc. advertising and digital
media from the company directly. There may be 3rd parties who may
have shares Avant Technologies Inc., and may liquidate their shares
which could have a negative effect on the price of the stock. This
compensation constitutes a conflict of interest as to our ability
to remain objective in our communication regarding the profiled
company. Because of this conflict, individuals are strongly
encouraged to not use this publication as the basis for any
investment decision. The owner/operator of MIQ own shares of Avant
Technologies Inc. which were purchased in the open market. MIQ
reserves the right to buy and sell, and will buy and sell shares of
Avant Technologies Inc. at any time thereafter without any further
notice. We also expect further compensation as an ongoing digital
media effort to increase visibility for the company, no further
notice will be given, but let this disclaimer serve as notice that
all material disseminated by MIQ has been approved by the above
mentioned company; this is a paid advertisement, and we own shares
of the mentioned company that we will sell, and we also reserve the
right to buy shares of the company in the open market, or through
other investment vehicles. While all information is believed to be
reliable, it is not guaranteed by us to be accurate. Individuals
should assume that all information contained in our newsletter is
not trustworthy unless verified by their own independent research.
Also, because events and circumstances frequently do not occur as
expected, there will likely be differences between any predictions
and actual results. Always consult a licensed investment
professional before making any investment decision. Be extremely
careful, investing in securities carries a high degree of risk; you
may likely lose some or all of the investment.
View original
content:https://www.prnewswire.com/news-releases/healthcare-ai-adoption-accelerates-as-industry-eyes-125-billion-growth-by-2028-302354609.html
SOURCE USA News Group
